Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer
This study is to evaluate the tolerance of albumin paclitaxel combined with apatinib and Camrelizumab in the second-line treatment of advanced gastric cancer to determine the maximum tolerable dose (MTD) of the combination.
Advanced Gastric Cancer
DRUG: Albumin-paclitaxel, Apatinib, Camrelizumab
Dose-Limiting Toxicity [DLT], Dose-Limiting Toxicity, Each 21 days up to Dose-Limiting Toxicity (12-13 months)
Incidence and degree of Adverse Events and Serious Adverse Events [Safety], Incidence and degree of Adverse Events and Serious Adverse Events, Until 30 day safety follow-up visit (Up to 14-18 months)|Objective Response Rate [ORR], Objective Response Rate, Up to 13-16 months|Duration of response [DoR], Duration of response, Up to 13-16 months|Time To Response [TTR], Time To Response, Up to 13-16 months|Disease Control Rate [DCR], Disease Control Rate, Up to13-16 months|Progression Free Survival [PFS], Progression Free Survival, Up to 13-16 months|Overall Survival [OS], Overall Survival, Up to 14-18 months
This is a Single arm, open, phase I / II clinical trial. The study was divided into tolerance observation stage (dose exploration stage) and efficacy expansion stage (dose expansion stage).

This study is to evaluate the tolerance of albumin-paclitaxel combined with apatinib and Camrelizumab in the second-line treatment of advanced gastric cancer to determine the maximum tolerable dose (MTD) of the combination.

The secondary objective was to evaluate the safety and efficacy of albumin- paclitaxel in combination with apatinib and Camrelizumab in the second-line treatment of advanced gastric cancer.